Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial.
Swaminathan S, Menon PA, Gopalan N, Perumal V, Santhanakrishnan RK, Ramachandran R, Chinnaiyan P, Iliayas S, Chandrasekaran P, Navaneethapandian PD, Elangovan T, Pho MT, Wares F, Paranji Ramaiyengar N. Swaminathan S, et al. Among authors: santhanakrishnan rk. PLoS One. 2012;7(12):e47400. doi: 10.1371/journal.pone.0047400. Epub 2012 Dec 14. PLoS One. 2012. PMID: 23251327 Free PMC article. Clinical Trial.
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, Menon PA, Padmapriyadarsini C, Ramachandran R, Chinnaiyan P, Suhadev M, Sakthivel R, Narayanan PR. Swaminathan S, et al. Am J Respir Crit Care Med. 2010 Apr 1;181(7):743-51. doi: 10.1164/rccm.200903-0439OC. Epub 2009 Dec 3. Am J Respir Crit Care Med. 2010. PMID: 19965813 Clinical Trial.
Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
Velayutham BV, Allaudeen IS, Sivaramakrishnan GN, Perumal V, Nair D, Chinnaiyan P, Paramasivam PK, Dhanaraj B, Santhanakrishnan RK, Navaneethapandian GP, Marimuthu MK, Kumar V, Kandasamy C, Dharuman K, Elangovan T, Narasimhan M, Rathinam S, Vadivelu G, Rathinam P, Chockalingam C, Jayabal L, Swaminathan S, Shaheed JM. Velayutham BV, et al. Among authors: santhanakrishnan rk. Clin Infect Dis. 2014 Nov 15;59(10):e142-9. doi: 10.1093/cid/ciu550. Epub 2014 Jul 14. Clin Infect Dis. 2014. PMID: 25028463 Clinical Trial.
Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial.
Gopalan N, Santhanakrishnan RK, Palaniappan AN, Menon PA, Lakshman S, Chandrasekaran P, Sivaramakrishnan GN, Reddy D, Kannabiran BP, Agiboth HKK, Krishnamoorthy V, Rathinam S, Chockalingam C, Manoharan T, Ayyamperumal M, Jayanthi N, Satagopan K, Narayanan R, Krishnaraja R, Sathiyavelu S, Kesavamurthy B, Suresh C, Selvachitiram M, Arasan G, Susaimuthu S, Rathinam P, Angamuthu P, Jayabal L, Murali L, Ramachandran R, Tripathy SP, Swaminathan S. Gopalan N, et al. Among authors: santhanakrishnan rk. JAMA Intern Med. 2018 Apr 1;178(4):485-493. doi: 10.1001/jamainternmed.2018.0141. JAMA Intern Med. 2018. PMID: 29507938 Free PMC article. Clinical Trial.
Characteristics of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and its influence on tuberculosis treatment outcomes in persons living with HIV.
Narendran G, Jyotheeswaran K, Senguttuvan T, Vinhaes CL, Santhanakrishnan RK, Manoharan T, Selvaraj A, Chandrasekaran P, Menon PA, Bhavani KP, Reddy D, Narayanan R, Subramanyam B, Sathyavelu S, Krishnaraja R, Kalirajan P, Angamuthu D, Susaimuthu SM, Ganesan RRK, Tripathy SP, Swaminathan S, Andrade BB. Narendran G, et al. Among authors: santhanakrishnan rk. Int J Infect Dis. 2020 Sep;98:261-267. doi: 10.1016/j.ijid.2020.06.097. Epub 2020 Jul 2. Int J Infect Dis. 2020. PMID: 32623087 Free article. Clinical Trial.
Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden.
Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, Senguttuvan T, Rathinam S, Ayyamperumal M, Satagopan K, Rajendran D, Manoharan T, Lakshmanan S, Paramasivam P, Angamuthu D, Ganesan M, Easudoss Arockia JW, Venkatesan RB, Lakshmipathy V, Shanmugham S, Subramanyam B, Shankar S, Mohideen Shaheed J, Dhanaraj B, Paranji Ramiyengar N, Swaminathan S, Chandrasekaran P. Gopalan N, et al. PLoS One. 2021 Sep 20;16(9):e0257647. doi: 10.1371/journal.pone.0257647. eCollection 2021. PLoS One. 2021. PMID: 34543329 Free PMC article.
Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial.
Padmapriyadarsini C, Oswal VS, Jain CD, Mariappan MV, Singla N, Kumar S, Daniel BD, Dave JD, Vadgama P, Ramraj B, Kant S, Bhatnagar AK, Shanmugam S, Paul D, Bharathi J, Palav M, Shah NV, Santhanakrishnan R, Dewan RK, Shekh N, Rathinam P, Sisara AB, Mankar SD, Bajpai J, Mittal U, Chauhan S, Kumar R, Parmar M, Mattoo SK, Jaju J; modified BPaL (mBPaL) Study Team. Padmapriyadarsini C, et al. Among authors: santhanakrishnan r. Clin Infect Dis. 2024 Dec 17;79(6):1375-1385. doi: 10.1093/cid/ciae388. Clin Infect Dis. 2024. PMID: 39194339 Clinical Trial.